The DOI matches its Crossref record; 1,861 of the 1,959 references it cites were found in a registry or an index; 7 of the 11 sources its claims cite were checked for support.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Open accessAbstract
Objective The objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other health care professionals and stakeholders, and individuals with diabetes and their caregivers. Methods The American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022. Selected studies from results of literature searches composed the evidence base to update 2015 recommendations as well as to develop new recommendations based on review of clinical evidence, current practice, expertise, and consensus, according to established American Association of Clinical Endocrinology protocol for guideline development. Results This guideline includes 170 updated and new evidence-based clinical practice recommendations for the comprehensive care of persons with diabetes. Recommendations are divided into four sections: (1) screening, diagnosis, glycemic targets, and glycemic monitoring; (2) comorbidities and complications, including obesity and management with lifestyle, nutrition, and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic kidney disease, and cardiovascular disease; (3) management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy; (4) education and new topics regarding diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations on cancer risk, nonpharmacologic components of pediatric care plans, depression, education and team approach, occupational risk, role of sleep medicine, and vaccinations in persons with diabetes. Conclusions This updated clinical practice guideline provides evidence-based recommendations to assist with person-centered, team-based clinical decision-making to improve the care of persons with diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Own method · 2 Partly supported · 1 Couldn’t confirm · 1 No basis given · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A glucose level ≥200 mg/dL in the presence of hyperglycemia symptoms such as polyuria and polydipsia confirm the diagnosis of DM.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Could not verifycites [6] sourceExperimental — accuracy not yet measured
The Diagnostic testing passage (page unavailable) discusses fasting glucose, HbA1c, C-peptide, and antibody tests for evaluating MODY. Neither it nor the other retrieved passages gives a ≥200 mg/dL glucose threshold with hyperglycemia symptoms for diagnosing diabetes; searches for that threshold and symptom-based criterion found no supporting passage in our copy. (LLM, conf=0.73)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The concordance between FPG, 2-hour PG, and A1C is not perfect; thus, the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Partly supportedcites [3] sourceExperimental — accuracy not yet measured
The paper’s introductory passage says diabetes diagnosis requires confirmation of an elevated glucose or HbA1c result and that two different tests above diagnostic thresholds can provide confirmation. It also says repeating the same test on a later sample is preferred, so two different tests are not required. The Discussion says guidelines were unclear about using two tests from one sample; our copy does not address the quoted exception for symptoms with glucose of at least 200 mg/dL or concordance involving 2-hour PG. (LLM, conf=0.87)
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The paper’s opening section says that FPG or 2-hour glucose meets the usual diagnostic criteria when abnormal on more than one occasion, and that classic symptoms with a single random plasma glucose of at least 200 mg/dL are diagnostic. It does not say that confirmation requires two different tests (FPG and A1C), or that two abnormal results from the same sample suffice. Its discussion of test variability supports imperfect reproducibility, but not that specific confirmation rule. (LLM, conf=0.88)
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Discussion reports imperfect agreement among HbA1c, fasting plasma glucose, and 2-hour plasma glucose, and says diabetes diagnosis requires repeated measurement rather than a single test. It does not specify that the two abnormal results must be from different tests, describe the same-sample or different-day options, or state an exception for hyperglycemic symptoms with glucose of at least 200 mg/dL. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Universal screening is recommended, as selective screening (only in women with risk factors) would miss a significant number of women with GDM and universal screening has been shown to be cost-effective compared with selective screening.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [50] sourceExperimental — accuracy not yet measured
The Conclusions recommend GDM screening at 24–28 weeks using a 75-g OGTT. The paper does not compare universal screening with risk-factor-based selective screening or report that universal screening is cost-effective; searches for selective screening and cost-effectiveness found no such comparison. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [51] source
- Not checked — no full text of the sourcecites [52] source
- Not checked — no full text of the sourcecites [53] source
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
Section 5.2 recommends universal testing because risk-factor-based selective testing has poor sensitivity for detecting GDM. But section 5.4 says there is a lack of good evidence for the cost-effectiveness of universal testing in both high- and low-resource countries; it does not establish that universal screening is cost-effective compared with selective screening. (LLM, conf=0.90)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Conclusions discuss childhood glucose outcomes after maternal GDM, not whether universal screening is recommended. Searches of our copy for selective screening, missed cases, and cost-effectiveness found no passage addressing those claims. (LLM, conf=0.76)
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Real-time CGM (rtCGM) or isCGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“DM is diagnosed by using any of 3 established criteria for elevated blood glucose (BG) concentrations (Table 4). FPG ≥126 mg/dL, 2-hour PG ≥ 200 mg/dL during 75-g OGTT, and A1C ≥ 6.5% are equally appropriate for diagnostic screening (Table 4).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For most hospitalized persons with hyperglycemia in both the intensive care unit (ICU) and non-ICU settings, a glucose range of 140 to 180 mg/dL is recommended, provided this target can be safely achieved (Table 6).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 2. What are the glycemic treatment goals for persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Diabetic peripheral neuropathy (DPN) is a clinical diagnosis. A comprehensive differential diagnosis should be considered to rule out nondiabetic neuropathies.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All persons who use insulin should use CGM or perform BG monitoring (BGM) a minimum of twice daily and ideally before any insulin injection.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A1C should be measured at least semiannually in all persons with DM and at least quarterly in persons not at their glycemic target.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Screening for DPN should be done at diagnosis of T2D, within 5 years of the diagnosis of T1D, and subsequently annually or whenever symptoms occur, by performing a clinical history and physical exam.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Continuous access to CGM for daily use is suggested for people living with T2DM at higher risk of hypoglycaemia, similar to the current CGM clinical practice guideline recommendations from Diabetes Canada 56 and the American Association of Clinical Endocrinologists. 57”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredIn the citing paper
“Approximately 2–5 times more patients discontinued orforglipron versus placebo due to adverse events, comparable to other GLP‐1 receptor agonists where 5%–15% discontinue in clinical trials [48].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [48]
In the citing paper
“Current guideline recommendations by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American College of Sports Medicine (ACSM), American Association of Clinical Endocrinology (AACE), and the American Heart Association (AHA) advocate regular resistance and aerobic exercise, as well as physical activity such as increasing daily steps to avoid sed”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
In the citing paper
“AACE and the ADA recommend avoiding no more than 2 to 3 days between exercise routines to maintain improvement in insulin sensitivity.”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven benefit is recommended as foundational therapy for persons with T2D and CKD with eGFR ≥20 mL/min/1.73 m2 to reduce progression of CKD and risk of CVD.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven kidney protection is recommended for people with T2D who have an eGFR >25 mL/min/1.73 m2 irrespective of albuminuria to reduce risks of DKD or CKD in DM and CVD.425,443–469 In those with HF, one agent in the class, empagliflozin, can be used with an eGFR as low as 20 mL/min/1.73 m2.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“The one-step approach uses a 2-hour 75-g oral glucose tolerance test (OGTT) after ≥8 hours of fasting with diagnostic cutoffs of one or more FPG ≥92 mg/dL, 1-hour PG ≥180 mg/dL, or 2-hour PG ≥153 mg/dL.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 3: Management of Prediabetes, T2D, and T1D With Selection of Glycemic Targets, Lifestyle Interventions, and Antihyperglycemic Pharmacotherapy (Insulin Therapy for all With T1D and Select Individuals With T2D); Prevention, Identification, and Treatment of Hypoglycemia; Treatment of Hospitalized Persons With DM or Those With Hyperglycemia Without Diagnosis of DM; and Women With GDM > Evidence Base 16: How should DM in pregnancy be managed?
“Glucose criteria diagnostic for GDM are an FPG >92 mg/dL, 1-hour postglucose challenge value ≥180 mg/dL, or 2-hour value ≥153 mg/dL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“A phase 2 study in persons with biopsy-proven NASH using a daily injection equivalent to semaglutide 2.4 g/week demonstrated 13% weight loss”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“Subcutaneous semaglutide at the higher dose of 2.4 mg/week has been approved for chronic weight management”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“Diagnosis of DM requires 2 abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
“the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Adler, 2021, Reprint of: Classification of diabetes mellitus, Diabetes Res Clin Pract, 10.1016/j.diabres.2021.108972”
Cited work 10.1016/j.diabres.2021.108972 · retracted 2021-07-31 · notice 10.1016/j.diabres.2021.108972 · this paper published 2022-10
Citations
Cites
1 retracted
Items 801–1,000 of 1,862
Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes
Maresh, M. J. A., Holmes, V. A., Patterson, C. C., Young, I. S., Pearson, D. W. M., Walker, J. D., & McCance, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-1755 · Cited by 175
Yamada, T., Shojima, N., Noma, H., Yamauchi, T., & Kadowaki, T. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4523-0 · Cited by 175
Lind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Lalmohamed, A., de Vries, F., Bazelier, M. T., Cooper, A., van Staa, T.-P., Cooper, C., & Harvey, N. C. (2012) · BMJ · doi:10.1136/bmj.e5085 · Cited by 173
Sulfonylureas: A New Look at Old Therapy
Thulé, P. M., & Umpierrez, G. E. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0473-5 · Cited by 173
Self-citationWeight gain as an adverse effect of some commonly prescribed drugs: a systematic review
Leslie, W. S., Hankey, C. R., & Lean, M. E. J. (2007) · QJM · doi:10.1093/qjmed/hcm044 · Cited by 173
Haugstvedt, A., Wentzel‐Larsen, T., Graue, M., Søvik, O., & Rokne, B. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02867.x · Cited by 172
Nicholson, A. S., Sklar, M., Barnard, N. D., Gore, S., Sullivan, R., & Browning, S. (1999) · Preventive Medicine · doi:10.1006/pmed.1999.0529 · Cited by 171
Menopause in Type 1 Diabetic Women
Dorman, J. S., Steenkiste, A. R., Foley, T. P., Strotmeyer, E. S., Burke, J. P., Kuller, L. H., & Kwoh, C. K. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1857 · Cited by 171
Itsiopoulos, C., Brazionis, L., Kaimakamis, M., Cameron, M., Best, J. D., O’Dea, K., & Rowley, K. (2011) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.03.005 · Cited by 171
Sympathetic dysfunction in type 1 diabetes
Pop-Busui, R., Kirkwood, I., Schmid, H., Marinescu, V., Schroeder, J., Larkin, D., Yamada, E., Raffel, D. M., & Stevens, M. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.033 · Cited by 170
Self-citationYao, K., Zeng, L., He, Q., Wang, W., Lei, J., & Zou, X. (2017) · Medical Science Monitor · doi:10.12659/msm.902600 · Cited by 170
Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline
Galindo, R. J., Umpierrez, G. E., Rushakoff, R. J., Basu, A., Lohnes, S., Nichols, J. H., Spanakis, E. K., Espinoza, J., Palermo, N. E., Awadjie, D. G., et al. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820954163 · Cited by 170
Self-citationSaed, L., Varse, F., Baradaran, H. R., Moradi, Y., Khateri, S., Friberg, E., Khazaei, Z., Gharahjeh, S., Tehrani, S., Sioofy-Khojine, A.-B., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5748-4 · Cited by 169
Pasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30402-8 · Cited by 168
Self-citationAmerican Diabetes Association Professional Practice Committee (2021) · Diabetes Care · doi:10.2337/dc22-s003 · Cited by 167
Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0012 · Cited by 167
Self-citationArnolds, S., Dellweg, S., Clair, J., Dain, M., Nauck, M. A., Rave, K., & Kapitza, C. (2010) · Diabetes Care · doi:10.2337/dc09-2191 · Cited by 167
Home-based exergaming among children with overweight and obesity: A randomized clinical trial
Staiano, A. E., Beyl, R. A., Guan, W., Hendrick, C. A., Hsia, D. S., & Newton, R. L. (2018) · Pediatric Obesity · doi:10.1111/ijpo.12438 · Cited by 167
Umpierrez, G. E., Gianchandani, R., Smiley, D., Jacobs, S., Wesorick, D. H., Newton, C., Farrokhi, F., Peng, L., Reyes, D., Lathkar-Pradhan, S., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0277 · Cited by 166
Self-citationEdelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166
Battling Insulin Resistance in Elderly Obese People With Type 2 Diabetes
Willey, K. A., & Singh, M. A. F. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1580 · Cited by 165
Rates of postpartum glucose testing after gestational diabetes mellitus
Russell, M. A., Phipps, M. G., Olson, C. L., Welch, H. G., & Carpenter, M. W. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000245446.85868.73 · Cited by 165
Vegetarian and vegan diets in type 2 diabetes management
Barnard, N. D., Katcher, H. I., Jenkins, D. J., Cohen, J., & Turner-McGrievy, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00198.x · Cited by 164
Marson, E. C., Delevatti, R. S., Prado, A. K. G., Netto, N. D. S., & Kruel, L. F. M. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.10.020 · Cited by 164
Kempf, K., Altpeter, B., Berger, J., Reuß, O., Fuchs, M., Schneider, M., Gärtner, B., Niedermeier, K., & Martin, S. (2017) · Diabetes Care · doi:10.2337/dc17-0303 · Cited by 164
Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T. (2019) · Diabetes Care · doi:10.2337/dc18-2388 · Cited by 164
Self-citationWinslow, D. H., Bowden, C. H., DiDonato, K. P., & McCullough, P. A. (2012) · Sleep · doi:10.5665/sleep.2204 · Cited by 163
Treatments for gestational diabetes: A systematic review and meta-analysis
Farrar, D., Simmonds, M., Bryant, M., Sheldon, T. A., Tuffnell, D., Golder, S., & Lawlor, D. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015557 · Cited by 163
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes in adolescence
Cameron, F. J., Garvey, K. C., Hood, K. K., Acerini, C. L., & Ethel Codner, D. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12702 · Cited by 163
Fokkert, M., van Dijk, P., Edens, M., Barents, E., Mollema, J., Slingerland, R., Gans, R., & Bilo, H. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000809 · Cited by 163
Barnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162
Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control
Inzucchi, S. E., Kosiborod, M., Fitchett, D., Wanner, C., Hehnke, U., Kaspers, S., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.118.035759 · Cited by 162
Self-citationNordwall, M., Abrahamsson, M., Dhir, M., Fredrikson, M., Ludvigsson, J., & Arnqvist, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1203 · Cited by 161
O'Brien, R., Johnson, E., Haneuse, S., Coleman, K. J., O'Connor, P. J., Fisher, D. P., Sidney, S., Bogart, A., Theis, M. K., Anau, J., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2383 · Cited by 161
Pasquel, F. J., Tsegka, K., Wang, H., Cardona, S., Galindo, R. J., Fayfman, M., Davis, G., Vellanki, P., Migdal, A., Gujral, U., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1168 · Cited by 161
Self-citationAbd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13924 · Cited by 160
Davis, G. M., Spanakis, E. K., Migdal, A. L., Singh, L. G., Albury, B., Urrutia, M. A., Zamudio-Coronado, K. W., Scott, W. H., Doerfler, R., Lizama, S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2856 · Cited by 160
Self-citationGenkinger, J. M., Kitahara, C. M., Bernstein, L., Berrington de Gonzalez, A., Brotzman, M., Elena, J. W., Giles, G. G., Hartge, P., Singh, P. N., Stolzenberg-Solomon, R. Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv355 · Cited by 159
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Approach to the patient with mody-monogenic diabetes
Broome, D. T., Pantalone, K. M., Kashyap, S. R., & Philipson, L. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa710 · Cited by 159
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia · doi:10.1007/s00125-014-3456-9 · Cited by 158
Diabetes and cancer: Epidemiological and biological links
Wang, M., Yang, Y., & Liao, Z. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i6.227 · Cited by 158
Medical conditions and motor vehicle collision injuries in older adults
Koepsell, T. D., Wolf, M. E., McCloskey, L., Buchner, D. M., Louie, D., Wagner, E. H., & Thompson, R. S. (1994) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1994.tb06526.x · Cited by 157
Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157
Al-Aly, Z., Qazi, R. A., González, E. A., Zeringue, A., & Martin, K. J. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.010 · Cited by 156
Structured Type 1 Diabetes Education Delivered Within Routine Care
Cooke, D., Bond, R., Lawton, J., Rankin, D., Heller, S., Clark, M., Speight, J., & for the U.K. NIHR DAFNE Study Group (2013) · Diabetes Care · doi:10.2337/dc12-0080 · Cited by 156
Use of influenza and pneumococcal vaccines in people with diabetes
Smith, S. A., & Poland, G. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.95 · Cited by 155
Galindo, R. J., Aleppo, G., Klonoff, D. C., Spanakis, E. K., Agarwal, S., Vellanki, P., Olson, D. E., Umpierrez, G. E., Davis, G. M., & Pasquel, F. J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820932903 · Cited by 155
Self-citationSingh, L. G., Satyarengga, M., Marcano, I., Scott, W. H., Pinault, L. F., Feng, Z., Sorkin, J. D., Umpierrez, G. E., & Spanakis, E. K. (2020) · Diabetes Care · doi:10.2337/dc20-0840 · Cited by 154
Self-citationDifferent strategies for diagnosing gestational diabetes to improve maternal and infant health
Farrar, D., Duley, L., Dowswell, T., & Lawlor, D. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007122.pub4 · Cited by 153
The Effect of Treatment of Obstructive Sleep Apnea on Glycemic Control in Type 2 Diabetes
Shaw, J. E., Punjabi, N. M., Naughton, M. T., Willes, L., Bergenstal, R. M., Cistulli, P. A., Fulcher, G., Richards, G. N., & Zimmet, P. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2260oc · Cited by 153
Wang, S. Y., Andrews, C., Herman, W. H., Gardner, T. W., & Stein, J. D. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.10.031 · Cited by 153
Self-citationMehta, S., Peynenburg, V. A., & Hadjistavropoulos, H. D. (2019) · Journal of Behavioral Medicine · doi:10.1007/s10865-018-9984-x · Cited by 153
Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.079 · Cited by 153
Ahmed, J., Ward, T. P., Bursell, S.-E., Aiello, L. M., Cavallerano, J. D., & Vigersky, R. A. (2006) · Diabetes Care · doi:10.2337/dc06-0295 · Cited by 152
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Hanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151
Lee, Y., & Park, K. (2017) · Nutrients · doi:10.3390/nu9060603 · Cited by 151
Voormolen, D. N., DeVries, J. H., Sanson, R. M. E., Heringa, M. P., de Valk, H. W., Kok, M., van Loon, A. J., Hoogenberg, K., Bekedam, D. J., Brouwer, T. C. B., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13310 · Cited by 151
Gylfadottir, S. S., Christensen, D. H., Nicolaisen, S. K., Andersen, H., Callaghan, B. C., Itani, M., Khan, K. S., Kristensen, A. G., Nielsen, J. S., Sindrup, S. H., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001744 · Cited by 151
Kuna, S. T., Reboussin, D. M., Strotmeyer, E. S., Millman, R. P., Zammit, G., Walkup, M. P., Wadden, T. A., Wing, R. R., Pi-Sunyer, F. X., Spira, A. P., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201912-2511oc · Cited by 151
McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa‐Rotter, R., Chertow, G. M., Greene, T., Held, C., Hou, F. F., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051675 · Cited by 151
Weiss, M., Sim, D. A., Herold, T., Schumann, R. G., Liegl, R. G.-H., Kern, C., Kreutzer, T. C., Schiefelbein, J. B., Rottmann, M., Priglinger, S. G., et al. (2017) · Retina · doi:10.1097/iae.0000000000001892 · Cited by 150
Lum, J. W., Bailey, R. J., Barnes-Lomen, V., Naranjo, D., Hood, K. K., Lal, R. A., Arbiter, B., Brown, A. S., DeSalvo, D. J., Pettus, J., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0535 · Cited by 150
Chu, P. Y., Maslow, G. R., von Isenburg, M., & Chung, R. J. (2015) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2015.05.022 · Cited by 149
Resolution of nonalcoholic steatohepatits after gastric bypass surgery
Liu, X., Lazenby, A. J., Clements, R. H., Jhala, N., & Abrams, G. A. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9086-2 · Cited by 149
Hopper, I., Billah, B., Skiba, M., & Krum, H. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711421687 · Cited by 149
Korytkowski, M. T., Salata, R. J., Koerbel, G. L., Selzer, F., Karslioglu, E., Idriss, A. M., Lee, K. K. W., Moser, A. J., & Toledo, F. G. S. (2009) · Diabetes Care · doi:10.2337/dc08-1436 · Cited by 149
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Self-citationInflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.12.002 · Cited by 147
Self-citationPioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147
Mann, J. F. E., Fonseca, V., Mosenzon, O., Raz, I., Goldman, B., Idorn, T., von Scholten, B. J., Poulter, N. R., & The LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Circulation · doi:10.1161/circulationaha.118.036418 · Cited by 147
The Statin Choice decision aid in primary care: A randomized trial
Mann, D. M., Ponieman, D., Montori, V. M., Arciniega, J., & McGinn, T. G. (2009) · Patient Education and Counseling · doi:10.1016/j.pec.2009.10.008 · Cited by 146
Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration
Woodcock, J., Sharfstein, J. M., & Hamburg, M. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1010788 · Cited by 146
Mudaliar, U., Zabetian, A., Goodman, M., Echouffo-Tcheugui, J. B., Albright, A. L., Gregg, E. W., & Ali, M. K. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002095 · Cited by 146
Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Procopio, M., Pagano, G. F., Cassader, M., & Gambino, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.010 · Cited by 146
Freisling, H., Arnold, M., Soerjomataram, I., O'Doherty, M. G., Ordóñez-Mena, J. M., Bamia, C., Kampman, E., Leitzmann, M., Romieu, I., Kee, F., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.106 · Cited by 145
Koye, D. N., Magliano, D. J., Reid, C. M., Jepson, C., Feldman, H. I., Herman, W. H., & Shaw, J. E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.02.364 · Cited by 145
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
Self-citationInfluence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia
Sharif, A., Moore, R., & Baboolal, K. (2008) · Transplantation · doi:10.1097/tp.0b013e3181605ebf · Cited by 144
Gibb, R. D., McRorie, J. W., Russell, D. A., Hasselblad, V., & D’Alessio, D. A. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.106989 · Cited by 144
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144
Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies
Esposito, K., Chiodini, P., Maiorino, M. I., Bellastella, G., Panagiotakos, D., & Giugliano, D. (2014) · Endocrine · doi:10.1007/s12020-014-0264-4 · Cited by 142
Stevens, J., Khunti, K., Harvey, R. C., Johnson, M., Preston, L., Woods, H. B., Davies, M. J., & Goyder, E. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.027 · Cited by 142
Miles, J. M., Rizza, R. A., Haymond, M. W., & Gerich, J. E. (1980) · Diabetes · doi:10.2337/diab.29.11.926 · Cited by 142
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
Bohula, E. A., Wiviott, S. D., Giugliano, R. P., Blazing, M. A., Park, J.-G., Murphy, S. A., White, J. A., Mach, F., Van de Werf, F., Dalby, A. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029095 · Cited by 142
Cunningham, A. T., Crittendon, D. R., White, N., Mills, G. D., Diaz, V., & LaNoue, M. D. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3186-7 · Cited by 142
Association of Sickle Cell Trait With Hemoglobin A1c in African Americans
Lacy, M. E., Wellenius, G. A., Sumner, A. E., Correa, A., Carnethon, M. R., Liem, R. I., Wilson, J. G., Sacks, D. B., Jacobs, D. R., Carson, A. P., et al. (2017) · JAMA · doi:10.1001/jama.2016.21035 · Cited by 141
Frequency of evidence-based screening for retinopathy in type 1 diabetes
The DCCT/EDIC Research Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612836 · Cited by 141
Pathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi‐Klug, R., Braffett, B. H., White, N. H., Sherwin, R. S., Service, F. J., Lachin, J. M., & Tamborlane, W. V. (2017) · Diabetes Care · doi:10.2337/dc16-2723 · Cited by 140
Self-citationGuo, F., Moellering, D. R., & Garvey, W. T. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2013.0128 · Cited by 139
Self-citationBressler, S. B., Glassman, A. R., Almukhtar, T., Bressler, N. M., Ferris, F. L., Googe, J. M., Gupta, S. K., Jampol, L. M., Melia, M., & Wells, J. A. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.025 · Cited by 139
Slentz, C. A., Bateman, L. A., Willis, L. H., Granville, E., Piner, L. W., Samsa, G. P., Setji, T. L., Muehlbauer, M. J., Huffman, K. M., Bales, C. W., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4051-z · Cited by 139
Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma
Rawla, P., Vellipuram, A. R., Bandaru, S. S., & Pradeep Raj, J. (2017) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-17-0081 · Cited by 139
Adolfsson, P., Hartvig, N. V., Kaas, A., Møller, J. B., & Hellman, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0411 · Cited by 139
Blood pressure control for diabetic retinopathy
Diana, V., Wang, X., Vedula, S. S., Marrone, M. T., Sleilati, G. G., Hawkins, B. S., & Frank, R. N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006127.pub2 · Cited by 138
Cavagnolli, G., Pimentel, A. L., Freitas, P. A. C., Gross, J. L., & Camargo, J. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171315 · Cited by 138
Ye, X., Kong, W., Zafar, M. I., & Chen, L.-L. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0851-z · Cited by 138
Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic
Agarwal, S., Mathew, J., Davis, G. M., Shephardson, A., Levine, A., Louard, R., Urrutia, A., Perez-Guzman, C., Umpierrez, G. E., Peng, L., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2219 · Cited by 138
Self-citationDonnan, P. T., Leese, G., & Morris, A. D. (2000) · Diabetes Care · doi:10.2337/diacare.23.12.1774 · Cited by 137
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Scherr, R. E., Linnell, J. D., Dharmar, M., Beccarelli, L. M., Bergman, J. J., Briggs, M., Brian, K. M., Feenstra, G., Hillhouse, J. C., Keen, C. L., et al. (2017) · Journal of Nutrition Education and Behavior · doi:10.1016/j.jneb.2016.12.007 · Cited by 137
Esposito, K., Chiodini, P., Bellastella, G., Maiorino, M. I., & Giugliano, D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01512.x · Cited by 136
Metabolic obesity phenotypes and risk of breast cancer in postmenopausal women
Kabat, G. C., Kim, M. Y., Lee, J. S., Ho, G. Y., Going, S. B., Beebe-Dimmer, J., Manson, J. E., Chlebowski, R. T., & Rohan, T. E. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0495 · Cited by 136
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
Hill, P., Cross, N. B., Barnett, A. N. R., Palmer, S. C., & Webster, A. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004759.pub2 · Cited by 135
Aguiar, E. J., Morgan, P. J., Collins, C. E., Plotnikoff, R. C., & Callister, R. (2014) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-11-2 · Cited by 135
Intravenous insulin nomogram improves blood glucose control in the critically ill
Brown, G. R., & Dodek, P. (2001) · Critical Care Medicine · doi:10.1097/00003246-200109000-00010 · Cited by 134
Obesity and risk of bladder cancer: A dose-response meta-analysis of 15 cohort studies
Sun, J.-W., Zhao, L.-G., Yang, Y., Ma, X., Wang, Y.-Y., & Xiang, Y.-B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119313 · Cited by 133
Fleg, J. L., Evans, G. W., Margolis, K. L., Barzilay, J. I., Basile, J., Bigger, J. T., Cutler, J. A., Grimm, R. H., Pedley, C. F., PETERSON, K. A., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07474 · Cited by 133
Self-citationYourman, L. C., Cenzer, I. S., Boscardin, W. J., Nguyen, B. T., Smith, A. K., Schonberg, M. A., Schoenborn, N. L., Widera, E. W., Orkaby, A., Rodriguez, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6084 · Cited by 133
Schoenthaler, A., Lancaster, K. J., Chaplin, W. F., Butler, M. J., Forsyth, J. M., & Ogedegbe, G. G. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004691 · Cited by 132
Vinik, A. I., Shapiro, D. Y., Rauschkolb, C., Lange, B., Karcher, K., Pennett, D., & Etropolski, M. S. (2014) · Diabetes Care · doi:10.2337/dc13-2291 · Cited by 131
Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum
Dagogo-Jack, S. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.126 · Cited by 131
Predicting Development of Proliferative Diabetic Retinopathy
Nwanyanwu, K. H., Talwar, N., Gardner, T. W., Wrobel, J. S., Herman, W. H., & Stein, J. D. (2012) · Diabetes Care · doi:10.2337/dc12-0790 · Cited by 131
Self-citationFujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C.W. Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P.H. Wilding, J. (2016) · Obesity · doi:10.1002/oby.21629 · Cited by 131
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Umpierrez, G. E., Reyes, D., Smiley, D., Hermayer, K., Khan, A., Olson, D. E., Pasquel, F., Jacobs, S., Newton, C., Peng, L., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0479 · Cited by 130
Self-citationvan Vught, L. A., Wiewel, M. A., Klein Klouwenberg, P. M. C., Hoogendijk, A. J., Scicluna, B. P., Ong, D. S. Y., Cremer, O. L., Horn, J., Bonten, M. M. J., Schultz, M. J., et al. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001650 · Cited by 130
Traish, A. M., Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417691136 · Cited by 130
Heitkemper, E. M., Mamykina, L., Travers, J., & Smaldone, A. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocx025 · Cited by 130
Wahabi, H. A., Fayed, A., Esmaeil, S., Elmorshedy, H., Titi, M. A., Amer, Y. S., Alzeidan, R. A., Alodhayani, A. A., Saeed, E., Bahkali, K. H., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0237571 · Cited by 130
(2009) · PubMed Central · Cited by 129
Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy
Callaghan, B. C., Kerber, K. A., Lisabeth, L. D., Morgenstern, L. B., Longoria, R., Rodgers, A. F., Longwell, P. J., & Feldman, E. L. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1279 · Cited by 129
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 129
Self-citationCardona-Hernandez, R., Schwandt, A., Alkandari, H., Bratke, H., Chobot, A., Coles, N., Corathers, S., Goksen, D., Goss, P., Imane, Z., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1674 · Cited by 129
for the KORA Study Group, Ziegler, D., Voss, A., Rathmann, W., Strom, A., Perz, S., Roden, M., Peters, A., & Meisinger, C. (2015) · Diabetologia · doi:10.1007/s00125-015-3534-7 · Cited by 128
Low-carbohydrate diet scores and risk of type 2 diabetes in men
de Koning, L., Fung, T. T., Liao, X., Chiuve, S. E., Rimm, E. B., Willett, W. C., Spiegelman, D., & Hu, F. B. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.004333 · Cited by 128
Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128
The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia
The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1335 · Cited by 128
Beddhu, S., Greene, T., Boucher, R., Cushman, W. C., Wei, G., Stoddard, G., Ix, J. H., Chonchol, M., Kramer, H., Cheung, A. K., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30099-8 · Cited by 128
Diabetes Prevention Program Research Group, Nathan, D. M., Knowler, W. C., Edelstein, S., Crandall, J. P., Dabelea, D., Goldberg, R. B., Kahn, S. E., Mather, K. J., Trandafirescu, G., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1970 · Cited by 128
Riddle, M. C., Henry, R. R., Poon, T., Bei, Z., Mac, S. M., Holcombe, J. H., Kim, D. D. H., & Maggs, D. G. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.646 · Cited by 127
Exercise increases cutaneous nerve density in diabetic patients without neuropathy
Singleton, J. R., Marcus, R. L., Jackson, J. E., K. Lessard, M., Graham, T. E., & Smith, A. G. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.125 · Cited by 127
Pandey, A., Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Martin, C. K., Balasubramanyam, A., Johnson, K. C., McGuire, D. K., Bertoni, A. G., Kitzman, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044865 · Cited by 127
Wahabi, H. A., Alzeidan, R. A., & Esmaeil, S. A. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-792 · Cited by 126
Nauck, M. A., Stewart, M. W., Perkins, C., Jones-Leone, A. R., Yang, F., Perry, C., Reinhardt, R. R., & Rendell, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3795-1 · Cited by 126
Šoupal, J., Petruželková, L., Flekač, M., Pelcl, T., Matoulek, M., Daňková, M., Škrha, J., Svačina, Š., & Prázný, M. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0171 · Cited by 126
Koro, C. E., Lee, B. H., & Bowlin, S. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.020 · Cited by 125
The Action for Health in Diabetes (Look AHEAD) Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0509 · Cited by 125
New-onset Diabetes After Distal Pancreatectomy: A Systematic Review
De Bruijn, K. M. J., & van Eijck, C. H. J. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000819 · Cited by 124
Sala-Vila, A., Díaz-López, A., Valls-Pedret, C., Cofán, M., García-Layana, A., Lamuela-Raventós, R.-M., Castañer, O., Zanon-Moreno, V., Martinez-Gonzalez, M. A., Toledo, E., et al. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.2906 · Cited by 124
Impact of Aging on the Strength of Cardiovascular Risk Factors: A Longitudinal Study Over 40 Years
Lind, L., Sundström, J., Ärnlöv, J., & Lampa, E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007061 · Cited by 124
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Cao, C., Yang, S., & Zhou, Z. (2020) · Endocrine · doi:10.1007/s12020-020-02223-6 · Cited by 124
Sacre, J. W., Franjic, B., Jellis, C. L., Jenkins, C., Coombes, J. S., & Marwick, T. H. (2010) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2010.09.014 · Cited by 123
Marinos, G., Eliades, C., Raman Muthusamy, V., & Greenway, F. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.03.005 · Cited by 123
Effects of a Pediatric Weight Management Program With and Without Active Video Games
Trost, S. G., Sundal, D., Foster, G. D., Lent, M. R., & Vojta, D. D. (2014) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2013.3436 · Cited by 123
Weber, M. A., Mansfield, T. A., Alessi, F., Iqbal, N., Parikh, S. J., & Ptaszynska, A. (2015) · Blood Pressure · doi:10.3109/08037051.2015.1116258 · Cited by 123
Rush, K. L., Hatt, L., Janke, R., Burton, L., Ferrier, M., & Tetrault, M. (2018) · Patient Education and Counseling · doi:10.1016/j.pec.2018.02.006 · Cited by 123
Cole, T. G., Contois, J. H., Csako, G., McConnell, J. P., Remaley, A. T., Devaraj, S., Hoefner, D. M., Mallory, T., Sethi, A. A., & Warnick, G. R. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196733 · Cited by 122
Sun, J., & Buys, N. J. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516000076 · Cited by 122
Sherr, J. L., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Rickels, M. R., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Fox, L. A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1606 · Cited by 122
Self-citationHalcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0591-5 · Cited by 122
Brown, F. M., & Wyckoff, J. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0922-z · Cited by 122
A priori-defined diet quality indexes and risk of type 2 diabetes: the multiethnic cohort
Jacobs, S., Harmon, B. E., Boushey, C. J., Morimoto, Y., Wilkens, L. R., Le Marchand, L., Kröger, J., Schulze, M. B., Kolonel, L. N., & Maskarinec, G. (2015) · Diabetologia · doi:10.1007/s00125-014-3404-8 · Cited by 121
Heerspink, H. J. L., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., McMurray, J. J. V., Rossing, P. R., Correa‐Rotter, R., Kurlyandskaya, R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab094 · Cited by 121
Self-citationInsulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis
Umpierrez, G. E., Jones, S., Smiley, D., Mulligan, P., Keyler, T., Temponi, A., Semakula, C., Umpierrez, D., Peng, L., Cerón, M., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0169 · Cited by 120
Self-citationMultiple risk behavior interventions: Meta-analyses of RCTs
Meader, N., King, K., Wright, K., Graham, H. M., Petticrew, M., Power, C., White, M., & Sowden, A. J. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.01.032 · Cited by 120
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14443 · Cited by 120
An assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119
Mayer, S. B., Jeffreys, A. S., Olsen, M. K., McDuffie, J. R., Feinglos, M. N., & Yancy, W. S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12191 · Cited by 119
Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30217-6 · Cited by 119
Self-citationCamelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000285 · Cited by 118
Bellido, V., Suarez, L., Rodriguez, M. G., Sanchez, C., Dieguez, M., Riestra, M., Casal, F., Delgado, E., Menendez, E., & Umpierrez, G. E. (2015) · Diabetes Care · doi:10.2337/dc15-0160 · Cited by 118
Self-citationTricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., Harrington, A., Wilson, C., Tsouros, S., Soobiah, C., et al. (2014) · BMJ · doi:10.1136/bmj.g5459 · Cited by 117
Shared decision making in endocrinology: Present and future directions
Rodriguez-Gutierrez, R., Gionfriddo, M. R., Ospina, N. S., Maraka, S., Tamhane, S., Montori, V. M., & Brito, J. P. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00468-4 · Cited by 117
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0936 · Cited by 117
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044359 · Cited by 117
Franz, M., Splett, P., Monk, A., Barry, B., McClain, K., Weaver, T., Upham, P., Bergenstal, R., & Mazze, R. (1995) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(95)00277-4 · Cited by 116
Small fiber neuropathy is associated with the metabolic syndrome
Pittenger, G. L., Mehrabyan, A., Simmons, K., Amandarice, Dublin, C., Barlow, P., & Vinik, A. I. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.113 · Cited by 116
Pop-Busui, R., Braffett, B. H., Zinman, B., Martin, C., White, N. H., Herman, W. H., Genuth, S., Gubitosi-Klug, R., & the DCCT/EDIC Research Group (2017) · Diabetes Care · doi:10.2337/dc16-1397 · Cited by 116
Self-citationVegetarian diet, change in dietary patterns, and diabetes risk: A prospective study
Chiu, T. H. T., Pan, W.-H., Lin, M.-N., & Lin, C.-L. (2018) · Nutrition & Diabetes · doi:10.1038/s41387-018-0022-4 · Cited by 116
Beddhu, S., Chertow, G. M., Greene, T., Whelton, P. K., Ambrosius, W. T., Cheung, A. K., Cutler, J. A., Fine, L. J., Boucher, R. E., Wei, G., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009326 · Cited by 116
Β cell dysfunction exists more than 5 years before type 1 diabetes diagnosis
Evans-Molina, C., Sims, E. K., DiMeglio, L. A., Ismail, H. M., Steck, A. K., Palmer, J. P., Krischer, J. P., Geyer, S., Xu, P., Sosenko, J. M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120877 · Cited by 116
Paula, T. P., Viana, L. V., Neto, A. T. Z., Leitão, C. B., Gross, J. L., & Azevedo, M. J. (2015) · The Journal of Clinical Hypertension · doi:10.1111/jch.12597 · Cited by 115
Remschmidt, C., Wichmann, O., & Harder, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0295-6 · Cited by 115
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115
Vitrectomy in the management of diabetic retinopathy
Smiddy, W. E., & Flynn, H. W. (1999) · Survey of Ophthalmology · doi:10.1016/s0039-6257(99)00036-3 · Cited by 114
Bode, B. W., McGill, J. B., Lorber, D. L., Gross, J. L., Chang, P.-C., Bregman, D. B., & for the Affinity 1 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0075 · Cited by 114
Self-citationAbdominal obesity and lung cancer risk: Systematic review and meta-analysis of prospective studies
Hidayat, K., Du, X., Chen, G., Shi, M., & Shi, B. (2016) · Nutrients · doi:10.3390/nu8120810 · Cited by 114
Juneja, R., Roudebush, C. P., Kumar, N., Macy, A., Golas, A. A., Wall, D., Wolverton, C. L., Nelson, D., Carroll, J. C., & Flanders, S. J. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0015 · Cited by 113
Misso, M. L. (2010) · Journal of Evidence-Based Medicine · doi:10.1111/j.1756-5391.2010.01094.x · Cited by 113
Agardh, E., & Tababat-Khani, P. (2011) · Diabetes Care · doi:10.2337/dc10-2308 · Cited by 113
Low-Volume High-Intensity Interval Training as a Therapy for Type 2 Diabetes
Álvarez, C., Ramírez‐Campillo, R., Martínez‐Salazar, C., Mancilla, R., Flores‐Opazo, M., Cano-Montoya, J., & Ciolac, E. G. (2016) · International Journal of Sports Medicine · doi:10.1055/s-0042-104935 · Cited by 113
Benkhadra, K., Alahdab, F., Tamhane, S. U., McCoy, R. G., Prokop, L. J., & Murad, M. H. (2017) · Endocrine · doi:10.1007/s12020-016-1039-x · Cited by 113
Baetge, C., Earnest, C. P., Lockard, B., Coletta, A. M., Galvan, E., Rasmussen, C., Levers, K., Simbo, S. Y., Jung, Y. P., Koozehchian, M., et al. (2017) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2016-0456 · Cited by 113
Abu-Ashour, W., Twells, L., Valcour, J., Randell, A., Donnan, J., Howse, P., & Gamble, J.-M. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000336 · Cited by 113
study, F. T. U., Shepherd, M. H., Shields, B. M., Hudson, M., Pearson, E. R., Hyde, C., Ellard, S., Hattersley, A. T., & Patel, K. (2018) · Diabetologia · doi:10.1007/s00125-018-4728-6 · Cited by 113
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Self-citationEvaluation of a hospital diabetes specialist nursing service: a randomized controlled trial
Davies, M. M., Dixon, S., Currie, C. J., Davis, R., & Peters, J. R. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00470.x · Cited by 112
Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis
Samah, S., Ramasamy, K., Lim, S. M., & Neoh, C. F. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.06.014 · Cited by 112
Raygan, F., Ostadmohammadi, V., Bahmani, F., & Asemi, Z. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.02.007 · Cited by 112
Pala, L., Dicembrini, I., & Mannucci, E. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01326-5 · Cited by 112
Giraldez, R. R., Clare, R. M., Lopes, R. D., Dalby, A. J., Prabhakaran, D., Brogan, G. X., Giugliano, R. P., James, S. K., Tanguay, J.-F., Pollack, C. V., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.005 · Cited by 111
Staiano, A. E., Marker, A. M., Beyl, R. A., Hsia, D. S., Katzmarzyk, P. T., & Newton, R. L. (2017) · Pediatric Obesity · doi:10.1111/ijpo.12117 · Cited by 111
Research works printed but not linked: 9
- Gillett, 2009, International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: Diabetes care, Clin Biochem Rev, 30, 197
- 1991, VIII. Study design, progress and performance, Diabetologia, 34, 877
- Nußbaumer, 2016, Ezetimibe-statin combination therapy, Dtsch arztebl int, 113, 445
- Whelton, 2018, Hypertens (Dallas. TX, 71, e13
- 2012, KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, 279
- Miller, 2015, Erratum. J Fam Pract, 64, 452
- Mechanick, 2019, Endocr Pract, 25, 1346
- 2019, Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study, Diabetes Care, 42, 601, 10.2337/dc18-1970 · DOI · Paper page
- American Diabetes Association. Medical management of pregnancy complicated by diabetes fourth edition. Jovanovic L, ed. Alexandria, VA: American Diabetes Association, 2009.
Cited by
Sorted by citations
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Self-citationDisorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Baricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
Honarmand, K., Sirimaturos, M., Hirshberg, E. L., Bircher, N. G., Agus, M. S. D., Carpenter, D. L., Downs, C. R., Farrington, E. A., Freire, A. X., Grow, A., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006174 · Cited by 177
Self-citationNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Self-citation
Metadata
- Authors
- Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., Gardner, T. W., Garg, R., Garvey, W. T., Hirsch, I. B., Hurley, D. L., Izuora, K., Kosiborod, M., Olson, D., Patel, S. B., Pop-Busui, R., Sadhu, A. R., Samson, S. L., Stec, C., Tamborlane, W. V., Tuttle, K. R., Twining, C., Vella, A., Vellanki, P., & Weber, S. L.
- Affiliations
- Ochsner Health System (US)
- Emory University (US)
- Central Michigan University (US)
- Washington University in St. Louis (US)
- University at Buffalo, State University of New York (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio (US)
- Scripps Whittier Diabetes Institute (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- Mayo Clinic (US)
- University of Nevada, Las Vegas (US)
- Saint Luke's Hospital (US)
- Colorado Health Foundation (US)
- University of Cincinnati Medical Center (US)
- Houston Methodist (US)
- Mayo Clinic in Florida (US)
- American Association of Clinical Endocrinologists (US)
- Yale University (US)
- Maine Medical Center (US)
- Prisma Health (US)
- ORCID
- Blonde, Lawrence
- Umpierrez, Guillermo E.
- McGill, Janet B.
- Berga, Sarah L.
- Bush, Michael
- Chandrasekaran, Suchitra
- DeFronzo, Ralph A.
- Einhorn, Daniel
- Galindo, Rodolfo J.
- Gardner, Thomas W.
- Garg, Rajesh
- Garvey, W. Timothy
- Hirsch, Irl B.
- Hurley, Daniel L.
- Izuora, Kenneth
- Kosiborod, Mikhail
- Patel, Shailendra B.
- Sadhu, Archana R.
- Samson, Susan L.
- Tamborlane, William V.
- Tuttle, Katherine R.
- Vella, Adrian
- Vellanki, Priyathama
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 923-1049
- ISSN
- 1530-891X (ISSN-L)
- PMC
- PMC10200071
- OpenAlex
- W4291397630
- Cited by
- 507
- References
- 1,959
- Citations by year
- 2026: 95 · 2025: 119 · 2024: 150 · 2023: 134 · 2022: 9
- FWCI
- 76.49
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-01)
- Open access
- bronze
- doi.org
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (K23DK123384, P30DK111024)
- National Institute of Diabetes and Digestive and Kidney Diseases
- BP
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- diabetes mellitus, comprehensive diabetes care, glycemic targets, blood glucose monitoring, diabetes complications, obesity, bariatric surgery, hypertension, dyslipidemia, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, cardiovascular disease, prediabetes, type 2 diabetes, type 1 diabetes, insulin therapy, hypoglycemia, diabetes in pregnancy, diabetes education, infertility, dietary supplements, social determinants of health, virtual care, cancer risk, pediatric diabetes care, depression, sleep medicine, team-based care
- MeSH terms
- Child, Diabetes Mellitus, Type 2, Endocrinology, Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, United States, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v1).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
